allergy disease News
-
BlueWillow Biologics Presents Positive Interim Anthrax Phase 1 Data to BARDA
BlueWillow Biologics, Inc. today announced that the company will present positive interim data from its phase 1 clinical trial of a novel intranasal anthrax vaccine at a Lightning Talks Session of BARDA’s Industry Day, November 3 and 4, 2021. BlueWillow’s rPA/NE01 anthrax vaccine, BW-1010, developed in collaboration with Porton Biopharma Limited (UK) and funded by the National ...
-
Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear detonation. “TP508 represents a natural product released at sites of tissue injury to ...
-
EU allergy and asthma network marks its achievements
The Global Allergy and Asthma European Network (GA2LEN)1, established in 2005 to facilitate excellence in allergy research across clinical and research institutions in Europe, has recently published a report on its major achievements. Funded by the EU, GA2LEN is composed of a multidisciplinary research network centred on scientific projects in allergy and asthma. It integrates research on ...
-
Indee Labs Awarded Grant from the National Institute of Allergy & Infectious Disease
Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery. The team at Indee Labs was awarded a grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop the µVS Delivery SystemTM for modified regulatory T cells. ...
By Indee Labs
-
Indee Labs Announces Successful Launch of Early Access Program
Indee Labs today announced the addition of three of the largest pharmaceutical companies, multiple biotechnology companies as well as Stanford's Cell Therapy Clinic and Moffitt Cancer Center, to participate in its Early Access Program. As part of the program, each participant receives temporary access to the Indee Labs platform and team for internal research and evaluation ...
By Indee Labs
-
Kephera Diagnostics awarded Phase II grant from the National Institute of Allergy and Infectious Diseases (NAID) for Zika virus test
Kephera Diagnostics announced today that it has been awarded a two-year, $1,989,300 Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), to complete the development and launch of a new test for Zika virus infection. Kephera’s test is aimed at detecting Zika ...
-
Creative Proteomics Cytokine Boosts Your Research and Discovery with Mouse Cytokine Assay
The Cytokine division belongs to Creative Proteomics, which specializes in providing cytokine research and analysis services for researchers in the pharmaceutical and biotechnology industries, as well as academic institutes and government agencies. Creative Proteomics Cytokine recently launched the Mouse Cytokine Assay with high sensitivity to support research in immune responses, inflammatory ...
-
Creative BioMart Established a Novel Sub-brand Creative BioMart Recombinant Allergen
Creative BioMart, an internationally recognized leading supplier of recombinant proteins, recently established a novel sub-brand “Creative BioMart Recombinant Allergen” that focuses on allergen-related study. Allergy is a common hypersensitivity disease in the world. It can be treated by allergen-specific immunotherapy (AIT). Natural allergen extracts do not meet the regulatory ...
-
INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022
INOVIO (NASDAQ: INO) announced today that fourth quarter 2021 financial results will be released after the market close on March 1, 2022. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. A live and archived version of the audio presentation will be available online at ...
-
Road pollution blamed for higher allergy risk in children
New evidence blames traffic-related pollution for increasing the risk of allergy and atopic diseases among children by more than fifty percent. What's more, the closer children live to roads, the higher their risk. '[Children] living very close to a major road are likely to be exposed not only to a higher amount of traffic-derived particles and gases but also to a more freshly emitted aerosols ...
-
BlueWillow Biologics Announces Positive Interim Results from Phase 1 Trial of Intranasal Anthrax Vaccine
BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced positive interim results from the Phase 1 clinical trial of BW-1010, its next-generation intranasal anthrax vaccine candidate. BW-1010 combines BlueWillow’s patented technology, a novel oil-in-water emulsion platform that efficiently presents antigens to the ...
-
ANGANY Gaining Momentum for Plant-Based Immunotherapy Platform
Canadian biotechnology company ANGANY (www.ANGANY.com) is presenting its immunotherapy platform at BIO International Convention, a critical rendez-vous for the global pharmaceutical industry which takes place in San Diego, California between June 13th and 16th. ANGANY’s primary focus is the development of therapeutic vaccines, leveraging the unique immunogenicity and safety profile of its ...
By Angany Inc.
-
INOVIO to Present at Oppenheimer`s 32nd Annual Healthcare Conference
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases, today announced that Dr. J. Joseph Kim, President and CEO, will participate in a reside chat and 1x1 investor meetings at Oppenheimer's 32nd Annual Healthcare Conference on Tuesday, March ...
-
Enrollment Begins for Latiglutenase (IMGX003) Phase 2b Trial for Treatment of Celiac Disease
ImmunogenX is pleased to announce that patient enrollment has begun for a Phase 2b clinical trial (NCT04243551, named “Solutions for Celiac”™). This trial is funded by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) as a grant to ImmunogenX. The multi-center trial includes Columbia University in New York, NY, Mayo ...
-
Siolta Therapeutics Awarded NIH Grant
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will provide funding for the continued ...
-
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the ...
-
Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development
Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs that target vascular endothelial and progenitor cells, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has provided additional funding in the amount of $587,995 to its contract with Chrysalis, bringing the ...
-
XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
-
Missing link in coronavirus jump from bats to humans could be pangolins, not snakes
As scientists scramble to learn more about the SARS-CoV-2 coronavirus, two recent studies of the virus’ genome reached controversial conclusions: namely, that snakes are intermediate hosts of the new virus, and that a key coronavirus protein shares “uncanny similarities” with an HIV-1 protein. Now, a study in ACS’ Journal of Proteome Research refutes both ideas and ...
-
World Health Organization Panel Strongly Recommends The Use Of Baricitinib To Treat Hospitalised Patients With COVID-19
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. BenevolentAI first identified baricitinib as a COVID-19 treatment candidate in January 2020 using its artificial intelligence (AI) platform. BenevolentAI was able to rapidly pinpoint ...
By Benevolent
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you